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Abstract 
 
Through this paper, we call for a distributed, 
internet-based collaboration to address one of the 
worst plagues of our present world, malaria. The spirit 
is a non-proprietary peer-production of information-
embedding goods. And we propose to use the grid 
technology to enable such a world wide “open source” 
like collaboration. The first step towards this vision 
has been achieved during the summer on the EGEE 
grid infrastructure where 46 million ligands were 
docked for a total amount of 80 CPU years in 6 weeks 
in the quest for new drugs.  
 
1. Introduction  
 
The number of cases and deaths from malaria 
increases in many parts of the world. There are about 
300 to 500 million new infections, 1 to 3 million new 
deaths and a 1 to 4% loss of gross domestic product (at 
least $12 billion) annually in Africa caused by malaria. 
The main causes for the comeback of malaria are 
that the most widely used drug against malaria, 
chloroquine, has been rendered useless by drug 
resistance in much of the world [17] and that 
anopheles mosquitoes, the disease vector, have become 
resistant to some of the insecticides used to control the 
mosquito population.  
Genomics research has opened new ways to find 
novel drugs to cure malaria, vaccines to prevent 
malaria, insecticides to kill infectious mosquitoes and 
strategies to prevent development of infectious 
sporozoites in the mosquito [2]. These studies require 
more and more in silico biology; from the first steps of 
gene annotation via target identification to the 
modelling of pathways and the identification of 
proteins mediating the pathogenic potential of the 
parasite. Grid computing supports all of these steps 
and, moreover, can also contribute significantly to the 
monitoring of ground studies to control malaria and to 
the clinical tests in plagued areas.   
It is well understood that the grid itself cannot drive 
drug development, but it can function as the catalyst 
that brings the actors (biochemists, physicians, etc) 
together and pushes them ahead in the same direction. 
 
2. Genomics research areas on malaria  
 
To increase the chances to develop new and better 
drugs and vaccines, it is very important to know the 
sequence of the genomes of the parasites that cause 
malaria as well as the specifics of gene and protein 
expression at different stages in the life cycle and 
under pressure from different drugs. 
The availability of genomic information for 
Anopheles gambiae, the major vector in Africa, and 
Plasmodium spec. enables us now to work out new 
approaches to interfere with the mechanism of the 
development of infectious sporozoites in anopheles 
mosquitoes and for reducing contact between 
infectious mosquitoes and humans. Much effort is also 
being devoted to biochemical and molecular studies of 
resistance mechanisms and to mapping of resistance 
genes. 
 
2.1. Development of vaccines 
 
In the development of vaccines, the value of 
knowing the sequences of certain genes and/or 
peptides is undeniable. It is known that susceptibility 
to Plasmodium can be entirely prevented for 9 months 
by immunizing with radiation attenuated sporozoites 
[1] and those children who live to 3 to 10 years of age 
in areas endemic for malaria rarely if ever develop 
severe malaria and die. If protective immunity requires 
induction of immune responses against 100 or even 
500 different target proteins, genomics research offers 
the most immediate way to identify those targets and to 
begin the process of developing vaccines based on 
them.  
However, progress has been painfully slow, and the 
few months duration of protection from the best 
currently available vaccine is inferior to what can be 
achieved with insecticide-treated nets or house 
spraying. When better vaccines eventually emerge, 
they should probably be used in conjunction with 
vector control to avoid their effects being hidden in 
areas of intense transmission. Whether vaccines and 
vector control synergize will have to be tested in the 
field and will not be predictable from molecular 
properties. 
 
2.2. Human susceptibility to malaria 
 
Knowledge of the human genome offers 
unprecedented potential for understanding who is and 
is not susceptible to dying from malaria, and who can 
benefit most from a particular type of vaccine. Having 
the human and parasite blueprint, and the 
computational biology capacity that goes with it, may 
allow developing a simple diagnostic that would 
identify at birth who is most at risk of dying from 
malaria. A single nucleotide polymorphism in the gene 
encoding the beta chain of human haemoglobin is 
associated with a 90% decrease in the chance of dying 
from a Plasmodium falciparum infection. Genomics 
research allows exploring if other SNPs or SNPs 
complexes in the human, anopheles and parasite 
genomes could impact the infection and the disease. 
 
2.3. Transgenesis  
 
There is also interest about transgenesis as a way to 
generate strains of mosquito that cannot transmit 
malaria. However, without extremely reliable systems 
for driving the transgenes into wild sector populations, 
possession of a non-transmitter strain would be of no 
practical use.  
A more feasible and acceptable way of using 
transgenesis may be to improve the sterile insect 
technique, which would only require release of non-
biting males. 
 
3. Rationale for a grid to address malaria 
 
For both vector control and chemotherapy, knowing 
the gene sequences of Anopheles and Plasmodium 
species should lead to discovery of targets against 
which new insecticides or antimalarial drugs can be 
produced. Genomics research is crucial to attacking 
malaria, but this research must be strongly coupled to 
ground studies in order to guide disease controllers, 
especially those working in countries with annual 
health budgets of less than $10 per person. Evaluation 
of the impact of new drugs and new vaccines require 
careful monitoring of clinical tests, especially in areas 
of high malaria transmission where it is important to 
distinguish recurrence of parasites, due to 
recrudescence of incompletely cured infections, from 
reinfection due to new mosquito bites. Disease 
controllers are also faced with the necessity to monitor 
goal-oriented field work on a long term.   
 
The grid technology provides the collaborative IT 
environment to enable the coupling between molecular 
biology research and goal-oriented field work. It 
proposes a new paradigm for the collection and 
analysis of distributed information where data are no 
more to be centralized in one single repository. On a 
grid, data can be stored anywhere and still be 
transparently accessed by any authorized user. The 
computing resources of a grid are also shared and can 
be mobilised on demand so as to enable very large 
scale genomics comparative analysis and virtual 
screening.      
 
The motivating perspective is to enhance the ability 
of both pharmaceutical industry and academic research 
institutions to share diverse, complex and distributed 
information on a given disease for collaborative 
exploration and mutual benefit. Leading international 
pharmaceutical groups such as Pfizer, Sanofi-Aventis 
and Novartis are already involved in activities of the 
United Nations / WHO to combat diseases of the poor. 
The goal here is to lower the barrier to such 
substantive interactions in order to produce cheaper 
drugs and insecticides to address diseases affecting 
third world development and to increase the return on 
investment for new drugs in the developed countries. 
 
4. Grid added value to address malaria 
 
4.1. In silico molecular biology  
 
Genomics research areas on malaria were discussed 
previously and include: 
 
- Search for targets on Anopheles 
genome and proteome for new 
insecticides  
- Search for targets on Plasmodium 
genomes and proteomes for new 
drugs (e.g. inhibitors of parasite 
development) 
- Identification of target proteins on 
Plasmodium proteomes to induce 
sustainable immune responses 
- Study of human susceptibility to 
malaria : identification of SNPs on 
human and Plasmodium genomes 
related to sensitivity  
- Study of Plasmodium and 
Anopheles genomics to prevent 
development of infectious 
sporozoites in anopheles 
mosquitoes  
- Study of mechanisms for drug 
resistance; including distributed 
monitoring of epidemiological 
parameters  
- Transgenesis to generate strains of 
mosquitoes that cannot transmit 
malaria 
 
These studies require extensive computing and 
storage resources. 
 
4.2. In silico drug discovery 
 
Virtual screening is about selecting in silico the best 
candidate drugs acting on a given target protein. 
Screening can be done in vitro using real chemical 
compounds, but this is a very expensive undertaking. 
If it could be done in silico in a reliable way, one could 
reduce the number of molecules requiring in vitro and 
then in vivo testing from a few millions to a few 
hundreds [15]. Advance in combinatorial chemistry 
has paved the way for synthesizing millions of 
different chemical compounds. Thus there are millions 
of chemical compounds available in pharmaceutical 
laboratories and also in a very limited number of 
publicly accessible databases.  
A coordinated public effort on in silico drug 
screening would require to set up a “public” collection 
of virtual compounds from existing compound 
databases and compound catalogues (PDB [9] Ligand 
Chemistry, KEGG-Ligand [10], compound catalogues, 
PubChem [21]…). This public compound repository 
should also comprise all information known about 
biological activities of the compounds in this 
repository. Moreover, information on possible 
strategies for the synthesis of these compounds should 
be available to speed up the in vitro testing of potential 
candidate drugs after in silico screening.     
In silico drug discovery should foster collaboration 
between public and private laboratories. It should also 
have an important societal impact by lowering the 
barrier to develop new drugs for rare and neglected 
diseases. 
 
4.3. Federation of databases for clinical tests in 
plagued areas 
 
Grid technology opens new perspectives for 
preparation and follow-up of medical missions in 
developing countries as well as support to local 
medical centres in terms of teleconsulting, 
telediagnosis, patient follow-up and e-learning [13]. In 
every hospital, patients are recorded in the databases 
which are federated in a network. Such a federation of 
databases allows medical data to be kept distributed in 
the hospitals behind firewalls. Views of the data are 
granted according to individual access rights through 
secured networks.     
Such a federation of databases can be used to 
monitor ground studies in developing countries. The 
data stored can be used for epidemiology purposes as 
well as clinical tests.   
In testing antimalarial drugs in areas of high malaria 
transmission, it is important to distinguish recurrence 
of parasites, due to recrudescence of incompletely cure 
infections, from reinfection due to new mosquito bites. 
Molecular matching of the parasite clones in the same 
individuals before and after treatment is a way of 
doing this.   
When better vaccines eventually emerge, they 
should probably be used in conjunction with vector 
control to avoid their effects being hidden in areas of 
intense transmission. Whether vaccines and vector 
control synergize will have to be tested in the field and 
will not be predictable from molecular properties. 
 
4.4. Knowledge space for disease information 
 
The goal is to make all relevant information on the 
disease available to all interested parties. The concept 
of a knowledge space is to organize the information so 
that it can be reached in a few clicks. This concept is 
already successfully used internally by pharmaceutical 
laboratories to store knowledge [14]. The grid allows 
building a distributed knowledge space so that each 
participant is able to keep the information he owns on 
his local computer. A set of grid services is proposed 
to make information easily consultable for the different 
potential customers (physicians, researchers, etc.). 
These services would take advantage of the 
developments in the area of semantic text analysis and 
text mining for extraction of information in biology 
and genome research. Moreover, a structured 
knowledge space would produce grid services for 
indexing of distributed data resources and thus 
improve navigation through knowledge and retrieval 
of relevant information. 
 
4.5. Monitoring of fieldwork to control malaria 
 
Monitoring tools to control malaria in plagued areas 
include reducing contacts between infected mosquitoes 
and humans by filling in breeding sites, larviciding, 
spraying houses with insecticides, insecticide-
impregnated bed nets, and house screening. Effective 
application of these measures would lead to reduce 
morbidity and mortality from malaria. However, given 
the extremely high transmission rate of Plasmodium 
falciparum, especially where Anopheles gambiae 
mosquitoes predominate, the impact of these tools can 
be limited by the capacity of mosquitoes to develop 
resistance and by the requirement for maintenance of 
the interventions for many years.  
Long term monitoring of these tools clearly would 
benefit of technologies allowing a better collection and 
analysis of distributed data in developing countries as 
is the case with grids.    
Indeed, internet is now accessible worldwide so the 
idea is to organize the collect of information around 
regional centres acting as local repositories. These 
repositories would be federated thanks to the grid 
technology at a world level for a general overview of 
the vector control work at the level of international 
agencies or non-profit organizations. 
 
5. Technology requirements for a malaria 
grid 
 
The goal of a grid for malaria would be to handle 
all aspects of the fight against malaria: 
 
- Search of new drug targets through 
post-genomics requiring data 
management and computing 
- Massive docking to search for new 
drugs requiring high performance 
computing and data storage 
- Handling of clinical tests and 
patent data requiring data storage 
and management 
- Overseeing the distribution of the 
existing drugs requiring data 
storage and management 
- Overseeing of vector control 
requiring data storage and 
management 
 
The grid should gather: 
 
- Biomedical laboratories searching 
for vaccines, working on the 
genomes of the parasite and/or the 
parasite vector and/or the human 
genome 
- Drug designers to identify new 
drugs 
- Healthcare centres involved in 
clinical tests 
- Healthcare centres collecting patent 
information 
- Structures involved in distributing 
existing treatments (healthcare 
administrations, non profit 
organizations…) and enforcing 
vector control  
- IT technology developers and 
computing centres 
 
The grid should provide the following services: 
 
- Large computing and storage 
resources for genomics research 
and virtual docking 
- Access to relevant genomes, 
regularly updated data bases and 
publications 
- Knowledge space with genomics 
and medical information 
(epidemiology, status of clinical 
tests, drug resistances, etc.) 
- Collaboration environment for the 
participating partners. No one 
entity can have an impact on all 
R&D aspects involved in 
addressing one disease as complex 
as malaria. The grid would act as a 
virtual laboratory of the different 
actors.   
- Federation of regional data bases 
for monitoring of vector control 
and clinical tests 
 
6. An open source approach to drug 
discovery 
 
The proposed grid to address malaria borrows the 
“open source” approach that has proven so successful 
in software development. Open source approaches 
have emerged in the biotechnology already. The 
international effort to sequence the human genome for 
instance resembled an open source initiative. It placed 
all the resulting data into the public domain rather than 
allow any participant to patent any of the results.  
 
The open source research on malaria could be 
organized as follows: a web site would allow chemists 
and biologists to volunteer their expertise on certain 
areas of the disease. They would examine and annotate 
shared databases and perform experiments. The results 
would be fully transparent and discussed in chat 
rooms. The research would be initially mainly 
computational, based on resources provided by grid 
infrastructures, and not carried out in “wet” 
laboratories.  
The difference between this proposal and earlier 
open source approaches in biomedical research is that 
scientists would collaborate on the data and not only 
on the software.    
The final development of drug candidates could be 
awarded to a laboratory based on competitive bids. 
The drug itself would go to public domain, for generic 
manufacturers to produce. This would achieve the goal 
of getting new medicines to those who need them at 
the lowest possible price. This model is currently 
supported by various programs of the United Nations 
and involves several commercial organisations, 
including large pharma companies. 
 
Open source research could also open the area of 
non-patentable compounds and drugs whose patents 
have expired. These receive very little attention from 
researchers because there would be no way to protect 
and so profit from any discovery that was made about 
their effectiveness. Lots of potentially useful drugs 
could be sitting under researchers noses. 
 
7. WISDOM, first step towards grid-
enabled virtual screening 
 
As discussed previously, in silico drug discovery is 
one of the most promising strategies to speed-up the 
drug development process. High throughput virtual 
screening allows screening millions of compounds 
rapidly, reliably and in a cost effective way. 
 
Grids like EGEE [4] are ideally suited for the first 
docking step where docking probabilities are computed 
for millions of ligands. It has been demonstrated 
during the summer 2005 by the WISDOM [16] 
initiative on malaria where 46 million ligands were 
docked for a total amount of 80 CPU years in 6 weeks. 
 
7.1. EGEE - an enabling grid for eScience 
 
The EGEE project [4] (Enabling Grid for E-
sciencE) brings together experts from over 27 
countries with the common aim of building on recent 
advances in Grid technology and developing a service 
Grid infrastructure which is available to scientists 24 
hours-a-day. The project aims to provide researchers in 
academia and industry with access to major computing 
resources, independent of their geographic location. 
The EGEE infrastructure is now a production grid with 
a large number of applications installed and used on 
the available resources. The infrastructure involves 
more than 180 sites spread in Europe, America and 
Asia.  
The WISDOM application was deployed within the 
framework of the biomedical Virtual Organization 
(VO). Figure 1 gives an overview of the geographical 
distribution of the resources node available for 
biomedical applications, which scale up to 3000 CPUs 
and 21 TB disk space. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Geographical distribution of EGEE 
biomedical resources in August 2005. The 
resources are spread over 15 countries. 
 
7.2. The WISDOM initiative 
 
WISDOM stands for World-wide In Silico Docking 
On Malaria. Its goal was to propose new inhibitors for 
a family of proteins produced by Plasmodium 
falciparum using in silico virtual docking on a grid 
infrastructure. The chosen target is involved in the 
haemoglobin metabolism, which is one the key 
metabolic processes in the survival of the parasite. 
There are several proteases involved in human 
haemoglobin degradation inside the food vacuole of 
the parasite inside the erythrocytes. Plasmepsin, the 
aspartic protease of Plasmodium, is responsible for the 
initial cleavage of human haemoglobin and later 
followed by other proteases [18]. There are ten 
different plasmepsins coded by ten different genes in 
Plasmodium falciparum (Plm I, II, IV, V, VI, VII, 
VIII, IX, X and HAP) [19]. High levels of sequence 
homology are observed between different plasmepsins 
(65-70%). Simultaneously they share only 35% 
sequence homology with its nearest human aspartic 
protease, Cathepsin D4 [20]. This and the presence of 
accurate X crystallographic data make plasmepsins 
ideal targets for rational drug design against malaria. 
Two docking software packages were used in 
WISDOM: one is FlexX [6], a commercial software 
made graciously available by BioSolveIT [12] for a 
limited time, and the other is Autodock [7], a software 
which is open-source for academic laboratories and 
which uses a different docking method. Chemical 
compounds were obtained from the ZINC database [8]. 
A subset of the ZINC database, the ChemBridge 
database (~500000 compounds), was docked using 
FlexX and Autodock. Another drug like subset 
(~500000 compounds) of ZINC database was docked 
using FlexX. 
 
7.3. WISDOM - results and perspectives 
 
During 6 weeks, 72751 jobs were launched for a 
total of 80 CPU years, producing 1 TB of data. A 
record number of 1643 jobs ran in parallel on 58 grid 
nodes, each representing from a few to more than 1000 
processors [5].  
First analysis of WISDOM results at Fraunhofer 
Institute (SCAI) has selected the 10,000 most 
promising compounds out of 1 million candidates 
using docking scores. The best scoring ligands include 
both known inhibitors and new ones. Most important 
is, that besides well established chemical core 
structures that share features with the already known 
plasmepsin inhibitors, new chemical entities were 
discovered. This is a first demonstration of the 
relevance of the in silico approach.  
Before in vitro experimentation, the best 
compounds will be re-ranked using molecular 
modelling within the framework of the BioInfoGrid 
European grid project. In parallel, a new massive 
deployment of in silico docking is foreseen on the 
EGEE infrastructure with new targets in the fall of 
2006. 
 
8. Conclusion 
 
Through this paper, we call for a distributed, 
internet-based collaboration to address one of the 
worst plagues of our present world, malaria. The spirit 
is a non-proprietary peer-production of information-
embedding goods. And we propose to use the grid 
technology to enable such a world wide “open source” 
like collaboration. The first step towards this vision 
has been achieved during the summer on the EGEE 
grid infrastructure where 46 million ligands were 
docked for a total amount of 80 CPU years in 6 weeks 
in the quest for new drugs. Further development of a 
grid-enabled virtual screening pipeline is underway in 
several European projects. 
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